We are excited to inform you that our study abstract on lenalidomide exposed RRMM patients has been accepted for poster presentation at the 64th annual ASH Conference in December 2022! Using real-world data from two HONEUR data partners (RMG and O.I.s), we were able to demonstrate that the Len-refractory population is a more difficult-to-treat patient population, with a high unmet need for effective treatments that can prolong survival outcomes for these patients.

Read the full abstract here